[The treatment of hyperkalemia with salbutamol].
For several years now, it has been known that the administering of adrenergic beta antagonists, especially of the beta-2 type, induce hypokalemia as a result of the entering of potassium into the skeletal muscle cells. This fall in kalemia occurs independently from the effect of insulin, aldosterone or kidney excretion, is mediated by the beta-2 receptors and require the intervention of cAMP joined at the cell membrane and the subsequent stimulation of the Na-K-ATPase which bring the potassium into the striated muscle cell. Among the most outstanding drugs with beta-2 effect is salbutamol, which maintains the hypokalemic effect whether administered intravenously or inhaled. It has been used in cases of hyperkalemia, in both children and adults. The initially used intravenous dosage (0.5 mg) caused several side-effects, especially rapid heart beat, seen more in children. It has been recently found that the use of doses as low as 4 micrograms/kg lower the kalemia to values averaging 1.4 to 1.6 mEq/L (mmol/L); in addition, using these dosages intravenously in an average of 20 minutes, no side-effects were seen, even when administered to newborns. For the above, we considered that salbutamol, in the suggested dosages, constitutes an efficient and secure therapeutic method for the initial treatment of severe hyperkalemic patients.
Velásquez
L
L
Departamento de Nefrología, Hospital Infantil de México Federico Gómez, D.F.
Muñoz
R
R
D000420:Albuterol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006947:Hyperkalemia / Q000188:drug therapy* / Q000378:metabolism; D007668:Kidney / Q000378:metabolism; D011188:Potassium / Q000378:metabolism; D011941:Receptors, Adrenergic / Q000378:metabolism
D011941:Receptors, Adrenergic; D000420:Albuterol; D011188:Potassium
Tratamiento de la hiperkalemia con salbutamol.